These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. Dittmann RW, Cardo E, Nagy P, Anderson CS, Adeyi B, Caballero B, Hodgkins P, Civil R, Coghill DR. CNS Drugs; 2014 Nov; 28(11):1059-69. PubMed ID: 25038977 [Abstract] [Full Text] [Related]
4. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine. Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P. Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974 [Abstract] [Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S. CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198 [Abstract] [Full Text] [Related]
7. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R. Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929 [Abstract] [Full Text] [Related]
9. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L. Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456 [Abstract] [Full Text] [Related]
11. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. May DE, Kratochvil CJ. Drugs; 2010 Oct; 70(1):15-40. PubMed ID: 20030423 [Abstract] [Full Text] [Related]
12. Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use. Jain R, Babcock T, Burtea T, Dirks B, Adeyi B, Scheckner B, Lasser R, Renna J, Duncan D. Adv Ther; 2013 May; 30(5):472-86. PubMed ID: 23681505 [Abstract] [Full Text] [Related]
13. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA. Eur J Health Econ; 2018 Jan; 19(1):21-35. PubMed ID: 28093662 [Abstract] [Full Text] [Related]
18. [Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe]. Häge A, Banaschewski T, Dittmann RW. Fortschr Neurol Psychiatr; 2015 Dec; 83(12):676-85. PubMed ID: 26714249 [Abstract] [Full Text] [Related]
20. The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders. Roncero C, Álvarez FJ. Expert Rev Neurother; 2014 Aug; 14(8):849-65. PubMed ID: 24948428 [Abstract] [Full Text] [Related] Page: [Next] [New Search]